Pressure continues to mount on embattled diagnostics company Theranos and its famous billionaire founder Elizabeth Holmes following a WSJ exposé that cast doubt on the accuracy of its tests and (little-used) Edison technology to detect diseases with just a few drops of blood. "I asked Theranos why my blood test results were wildly off from my 'traditional' labs, but no one ever replied" is the self-explanatory title of a piece in Quartz by Jean-Louis Gassée, a venture partner at Silicon Valley's Allegis Capital. The WSJ's findings hit insiders like Gassée hard because, as he writes, "Holmes' story is quintessential Silicon Valley. A Stanford drop-out who learned Mandarin and then sold C++ compilers to Chinese universities, Holmes holds more than a dozen patents, is financed by prominent venture investors, and has ascended to the financial pinnacle (Theranos, still private, is said to be worth $9 billion, of which Holmes would own about $4.5 billion)." The passage begs the (unanswered) question: is the development of an overhyped (but still potentially useful) technology part of that narrative too? More | Here's previous FMD coverage of the development | More